Drug Trial Radar · NCT04414761
Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response
Last checked: Nov 19, 2026Latest source record: Aug 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
784
Actual
Start
Jun 4, 2020
Primary completion
Oct 10, 2022
Study completion Oct 10, 2022
Sponsor
- Lead sponsor
- ShangHai Ji Ai Genetics & IVF InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years, up to 43 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Progestin can inhibit the pituitary LH surge during ovarian stimulation and various studies show progestin-primed ovarian stimulation (PPOS) is effective in blocking the LH surge in IVF. More and more centers in China are using PPOS because this regimen appears simpler and cheaper.A randomized trial to compare the effectiveness of PPOS and GnRH antagonist protocol in IVF in terms of the live birth rate is urgently needed. Trial objectives: To compare the live birth rate between the PPOS protocol and the antagonist protocol used for ovarian stimulation during IVF Eligible women will be randomised into one of the two groups: Antagonist group : Women will receive antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. PPOS group: Women will receive oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger. There will be no fresh transfer. Only one blastocyst will be allowed to replaced in the first FET and a maximum of two blastocysts will be replaced in the subsequent FET cycles. The primary outcome is the live birth rate of the first frozen-thawed transfer cycle.
Conditions
- IVF
- GnRH Antagonist
- PPOS
Interventions
ProgesteroneDrug
oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger
GnRH AntagonistDrug
GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Primary outcomes
What the sponsor says the trial is designed to measure.
- live birth rateTime frame: deliveries ≥22 weeks gestation with heartbeat and breath
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ShangHai JIAI Genetics&IVF Institute
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.